RHHBY Enicepatide: 62% Normoglycemia Tops GLP-1

Roche just put up the best blood-sugar number in the GLP-1 race, and the market shrugged. On September 22, Roche reported that enicepatide, its once-weekly dual GLP-1/GIP agonist, restored normal blood sugar in 62% of people with type 2 diabetes in a Phase 2 trial. That is the highest normoglycemia rate any drug in this class has reported, ahead of Lilly’s tirzepatide at 51% and Lilly’s triple-agonist retatrutide at roughly 31%. Roche’s ADR (RHHBY) closed at $54.80, essentially flat on the news. The non-reaction is the story in miniature: the data is real, the timeline is late, and a $352 billion company does not re-rate on a Phase 2 glucose readout.

The data

CT-388-104 (NCT06628362) was a randomized, double-blind, placebo-controlled Phase 2 trial across 447 adults with type 2 diabetes and overweight or obesity. The dual primary endpoints were change in HbA1c and change in body weight at 48 weeks, and both hit.

At the top 24 mg dose, HbA1c fell 2.65% from a baseline of 8.1%. Ninety percent of those patients got below 6.5%, the diagnostic threshold for diabetes, and 62% reached full normoglycemia, an HbA1c under 5.7% that is indistinguishable from a non-diabetic reading. For patients starting with poor control, an HbA1c above 8.5%, the drop was 4.13%. Weight loss averaged 15.5% at 48 weeks with no plateau, and only 2.0% discontinued for adverse events.

One caveat Roche did not volunteer. The press release omitted the placebo arm, so the 2.65% and 15.5% figures are absolute, not placebo-adjusted. In this class placebo typically subtracts half a point of HbA1c and two to three points of body weight, so the placebo-adjusted numbers are closer to a 2-point HbA1c drop and a 12 to 13% weight loss. Still strong. Just not the headline Roche would like you to read.

Why normoglycemia is the number that matters

Type 2 diabetes affects nearly 600 million adults worldwide, and the complications, blindness, kidney failure, stroke, and amputation, are what make it expensive and lethal. Most GLP-1 drugs get patients to “controlled” diabetes, an HbA1c under 7%. Very few get a meaningful fraction of patients all the way to a normal, non-diabetic blood sugar. That is the difference between managing a disease and reversing it. A 62% normoglycemia rate means nearly two-thirds of treated patients had a blood-sugar reading indistinguishable from someone without diabetes inside a year. That is the bar that separates enicepatide from the pack, and it is the number Roche’s Chief Medical Officer leaned on when he called the data a potential best-in-disease profile.

The mechanism

Enicepatide is a “dually biased” GLP-1/GIP agonist, engineered to activate both receptors while minimizing beta-arrestin recruitment. In plain English, most incretin drugs bind their receptor and then drag it inside the cell, which desensitizes the receptor over time and blunts the effect. Enicepatide is designed to bind and keep signaling without triggering that internalization, so the effect is supposed to last longer and run deeper. That is the scientific bet that this is not just another incretin but a genuinely different molecule, and it is the only reason a 2028 entrant could credibly claim differentiation rather than me-too status.

The competitive math

Against the drugs that matter, enicepatide wins on glucose. Lilly’s tirzepatide (Mounjaro/Zepbound) produced a 2.30% HbA1c reduction at 15 mg in SURPASS-2 and got 51% of patients to normoglycemia at that dose (NEJM, SURPASS-2). Novo’s semaglutide 1 mg managed 19% normoglycemia in the same trial. Lilly’s retatrutide, the triple GLP-1/GIP/glucagon agonist, reached 31% normoglycemia in its Phase 2 diabetes study and posted a 1.9% HbA1c reduction in Phase 3 TRANSCEND-T2D-1. Enicepatide’s 62% normoglycemia and 2.65% HbA1c reduction beat all three on glucose, and its 15.5% weight loss sits between tirzepatide’s roughly 12% and retatrutide’s 16.8%, without the glucagon axis that adds retatrutide’s potency but also its nausea and vomiting burden.

That is the bull case, stated plainly: class-leading glycemic control, near-triple-agonist weight loss, and a clean tolerability profile, all in one molecule.

The problem: Roche is late

The problem is the same one Roche has had since it paid $2.7 billion for Carmot Therapeutics: timing. The acmopatide discontinuation and the enicepatide obesity readout landed in July. Roche killed acmopatide and concentrated the Carmot bet on enicepatide, and this T2D readout is the first real vindication of that call. But the timeline has not moved. Two Phase 3 weight-management trials, ENITH-1 and ENITH-2, are ongoing, the Phase 3 glycemic program and a cardiovascular outcomes trial do not start until the first half of 2027, and a filing is not expected until 2028.

That is the entire trade. Lilly’s retatrutide Phase 3 TRIUMPH data is already in hand. Novo’s CagriSema head-to-head against tirzepatide is reading out. The obesity market is projected above $100 billion, and Roche is aiming to launch into it in 2028 as the third or fourth entrant, two years behind a fully formed competitive picture. A 62% normoglycemia number does not buy formulary position. Real-world evidence, a launched sales force, and established payer contracts do, and Roche has none of those in metabolic disease today.

Valuation: pipeline signal, not a stock catalyst

Do the arithmetic. Roche is a $352 billion company. If enicepatide reaches $10 billion in peak sales, that is roughly 3% of group revenue, arriving in the early 2030s and discounted for failure risk and time. Meaningful for the pharma division, close to a rounding error for the share price today. This is a pipeline signal, not a stock catalyst, and the market is pricing it correctly.

The class context makes the immateriality point sharper. Lilly, the GLP-1 leader, trades at $1.06 trillion, nearly the entire valuation resting on tirzepatide, retatrutide, and orforglipron. Novo Nordisk, whose semaglutide and CagriSema franchises are the incumbent standard of care, has cratered to $169 billion, down 27% in 2026 after guiding to an adjusted sales decline and cutting 9,000 jobs. Roche, with no metabolic franchise at all, sits at $352 billion, worth twice the Novo Nordisk that actually sells the drugs enicepatide is chasing. That is the honest signal: the market pays up for the whole obesity franchise and punishes stumbles brutally. Enicepatide is not yet in either camp, and a Phase 2 glucose number will not put it there.

What to watch

The ENITH-1 and ENITH-2 readouts come first, and they will tell us whether the no-plateau weight loss holds up at scale. The Phase 3 glycemic and cardiovascular outcomes program starts in the first half of 2027, which is the real proof Roche is serious about a full diabetes franchise. The obesity filing follows around 2028. The cardiovascular outcomes trial is where the durable value sits, because a GLP-1 that wins a cardiovascular indication becomes a formulary staple rather than a niche obesity option, and that readout is the better part of a decade away.

Verdict

RHHBY at $54.80 is a Hold. The data is best-in-disease on glucose, and enicepatide could still become a major franchise by 2030. But a Phase 2 glucose readout changes none of the two things that actually move a mega-cap pharma stock: the Phase 3 diabetes program has not started, and the launch is years behind Lilly and Novo. If you want to trade the GLP-1 story, you are already in LLY or NVO. Roche is a diversified pharma you own for other reasons, and enicepatide is a free option, not a thesis. The specific risk to watch is whether ENITH-1 and ENITH-2 replicate the no-plateau weight loss at scale, because a single-trial Phase 2 number compressing in Phase 3 is the most common way these programs die.

Source: Roche press release, September 22, 2026